Physician profile
Sheila Wright
NPI 1659629665
$3,729.65
in general payments reported to CMS, 2019-2025
20 companies · $1,411 in 2025
The $1,411 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $524 · 2023: $391 · 2024: $1,074 · 2025: $1,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $721.58 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $507.18 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $458.94 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $352.47 | 2023-2025 | Auvelity |
| Abbvie INC. | $317.14 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $299.30 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $278.27 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $223.33 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $141.16 | 2024-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $102.86 | 2022-2024 | |
| Novo Nordisk INC | $80.64 | 2025 | |
| Janssen Pharmaceuticals, INC | $79.31 | 2022 | |
| Lilly USA, LLC | $34.95 | 2025 | Jardiance |
| Lundbeck LLC | $22.83 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $19.98 | 2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.37 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $18.87 | 2025 | Voquezna |
| Amgen INC. | $18.38 | 2025 | Otezla, Repatha |
| Indivior INC. | $17.25 | 2021 | |
| Tris Pharma INC | $15.84 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.